< Back to search
Filter
1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

for
Solid Tumors With HRAS Alterations,
Location: Boston MA, New Brunswick NJ, Pittsburgh PA,
Sponsor: Kura Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06026410

Phase1, Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

for
Renal Cell Carcinoma (RCC),
Location: Boston MA, New Haven CT, New York NY, Hackensack NJ,
Sponsor: Exelixis

Sex: All

Age: 18+

Code: NCT05176483

Phase1, Recruiting

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

for
Renal Cell Carcinoma
Location: Boston MA, Ann Arbor MI, Houston TX, Dallas TX,
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06053658

Phase2, Recruiting

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

for
Solid Tumor, Small Cell Lung Cancer (SCLC),
Location: Fort Worth TX, West Valley City UT, Los Angeles CA
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT07517198

Phase1, Recruiting

Interested in new non-clear cell renal cell carcinoma trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image